[{"id":"1da2b0c6-165f-4d0a-a3e8-ec861405f022","acronym":"BGB-3111-402","url":"https://clinicaltrials.gov/study/NCT05640102","created_at":"2022-12-07T16:57:49.810Z","updated_at":"2025-02-25T17:02:16.646Z","phase":"","brief_title":"Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia","source_id_and_acronym":"NCT05640102 - BGB-3111-402","lead_sponsor":"BeiGene","biomarkers":" MYD88","pipe":" | ","alterations":" MYD88 mutation • MYD88 L265P • MYD88 wild-type","tags":["MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 mutation • MYD88 L265P • MYD88 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/03/2023","start_date":" 03/03/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-03"},{"id":"c81f0280-85de-45ec-aa26-8f5b43ba0005","acronym":"","url":"https://clinicaltrials.gov/study/NCT05734495","created_at":"2023-02-21T16:01:35.955Z","updated_at":"2024-07-02T16:35:10.696Z","phase":"Phase 2","brief_title":"Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia","source_id_and_acronym":"NCT05734495","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2 • MYD88","pipe":" | ","alterations":" MYD88 wild-type","tags":["BCL2 • MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Jaypirca (pirtobrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 05/02/2023","start_date":" 05/02/2023","primary_txt":" Primary completion: 01/25/2029","primary_completion_date":" 01/25/2029","study_txt":" Completion: 01/25/2033","study_completion_date":" 01/25/2033","last_update_posted":"2024-04-09"}]